Anderson Karen M. 4

What Happened Karen M. Anderson, Chief People Officer of Centessa Pharmaceuticals (CNTA), had a small disposition and two awards reported. On 2026-02-01 she had 10,606 shares withheld/sold at $24.57 each to cover tax obligations (gross proceeds/value = $260,589). On 2026-02-02 she was awarded/received 29,000 shares (no cash price) and a 117,000-share derivative award (no cash price), both reported as grants/awards.

Key Details

• Transactions reported: 2026-02-01 (10,606 shares withheld/sold at $24.57; $260,589) and 2026-02-02 (29,000 shares granted; 117,000 derivative award granted; both $0 cash price).
• Shares owned after transaction: not specified in the filing.
• Notable footnotes from the filing:
  • F1: Ordinary Shares may be represented by American Depositary Shares (1 ADS = 1 Ordinary Share).
  • F2: The 10,606-share disposition represents shares withheld by the issuer to cover tax withholding on vesting.
  • F3: Certain awards are Restricted Share Units (RSUs) under the company plan; RSUs vest/settle in four equal annual installments with the first vesting on Feb 2, 2027.
  • F4: Another award is subject to 1/48th monthly vesting, with the first installment vesting on Mar 2, 2026.
• Filing info: Form 4 filed 2026-02-03 (Accession 0001470831-26-000086); this appears to be filed timely. Exhibit 24.2 (Substitute Power of Attorney) is attached.

Context

• The 10,606-share sale was a tax-withholding disposition (routine administrative action), not an opportunistic open‑market sale. The grants (RSUs / derivative award) are compensation awards that vest over time — they do not represent an immediate market purchase or sale. For retail investors, awards indicate executive compensation alignment with the company but are not the same signal as an insider buying stock with cash.